Ultralife Corporation ULBI
6.16
0.26
4.41%
as of 25 Sep
- Market cap
- $100.8M
- P/E
- 0.0×
Follow ULBI
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
1.26% | (4.46%) | (6.17%) | (4.83%) | |
| 0.87% | (2.70%) | (3.70%) | (3.00%) | ||
ROIC |
2.16% | (2.16%) | (3.53%) | (3.05%) | |
Return on Tangible Assets |
1.60% | (5.42%) | (7.66%) | (5.99%) | |
Average Days of Receivables |
60.52 | 64.82 | 66.89 | 67.78 | |
Free Cash Flow per Share |
0.54 | 0.43 | 0.37 | 0.12 | |
Free Cash Flow |
8.95 | 7.12 | 6.13 | 2.03 | |
Capital Expenditures |
(3.60) | (3.87) | (3.75) | (3.10) | |
Piotroski F-Score |
3.00 | 4.00 | 3.00 | 3.00 | |
| Other line items | |||||
Cash ROIC |
6.37% | 5.81% | 5.30% | 2.79% | |
Accounts Receivable Turnover |
6.36 | 6.04 | 5.33 | 5.58 | |
Accounts Payable Turnover |
10.58 | 9.19 | 7.10 | 7.53 | |
Inventory Turnover |
2.94 | 2.75 | 2.75 | 2.59 | |
Average Days of Payables |
36.42 | 43.82 | 60.78 | 58.26 | |
Days of Inventory on Hand |
135.61 | 135.82 | 144.73 | 151.44 | |
Tax Rate |
(0.25) | (0.29) | (0.28) | (0.31) | |
Research and Development Expense of Revenue |
5.36% | 5.44% | 5.83% | 6.34% | |
Selling, General and Administrative Expense of Revenue |
15.22% | 15.35% | 15.84% | 15.99% | |
Share Based Compensation of Revenue |
0.49% | 0.49% | 0.38% | 0.30% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
7.30 | (1.86) | (1.20) | (0.78) | |
Depreciation/Fixed assets |
0.14 | 0.14 | 0.14 | 0.14 | |
Capex/Depreciation |
(0.64) | (0.67) | (0.65) | (0.55) | |
Revenue per Share |
11.21 | 11.49 | 11.28 | 11.24 | |
Operating CF per Share |
0.75 | 0.66 | 0.59 | 0.31 | |
Capex per Share |
(0.22) | (0.23) | (0.22) | (0.19) | |
Capex to Sales |
0.02 | 0.02 | 0.02 | 0.02 | |
Net Profit Margin |
0.92% | (3.09%) | (4.37%) | (3.50%) |
Columns are period end dates